PUBLISHER: DataM Intelligence | PRODUCT CODE: 1374850
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1374850
Migraine nasal sprays can provide relief to migraine patients in as soon as 15 minutes and are especially useful with nausea and vomiting or in those who seek to avoid an injection. These nasal sprays are most commonly used for the treatment of various types of migraine. They are sprayed into the nostril with the head upright. However, vigorous sniffing or tipping the head backward puts the medicine down the throat, turning a spray into an oral medication and losing the advantages of rapid nasal delivery.
Moreover, there are several categories of nasal spray treatment, including nasal triptans such as sumatriptan and zolmitriptan and dihydroergotamine (DHE) which contain migraine-specific treatment. Triptans and DHE are highly effective but it has some risk factors by causing blood vessel narrowing and should not be used in people with known or suspected vascular disease. A third nasal option is a non-steroidal anti-inflammatory (NSAID) spray, nasal ketorolac, containing medicine targeting migraine inflammation. This nasal delivery is very effective for treating migraine.
The increasing demand for novel advancements in migraine nasal sprays is expected to drive the market over the forecast period. The novel advanced nasal spray is launched which offers the best options to many patients to treat various migraines. The advancements also aim to address the unmet needs associated with the treatment of migraines with rapid response by providing alternative or complementary treatment options for better patient outcomes.
For instance, on March 10, 2023, Pfizer Inc. cleared the U.S. Food and Drug Administration (FDA) approval of ZAVZPRET (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. The FDA approval is based on two pivotal randomized, double-blind, placebo-controlled studies that established the efficacy, tolerability and safety profiles of ZAVZPRET for the acute treatment of migraine.
Moreover, advanced migraine nasal sprays are favored for their rapid onset of action. The medication can be absorbed quickly through the nasal mucosa after spraying it into the nostrils, offering faster relief compared to oral medications. Many migraine patients most commonly prefer nasal sprays because they are easy to use and do not require swallowing a pill, which can be challenging during a migraine attack, this increases the demand for novel advancements in migraine nasal sprays. Many pharmaceutical companies focus on developing these nasal sprays.
For instance, on June 13, 2023, Vistagen, a clinical-stage biopharmaceutical company released that the European Patent Office (EPO) issued an intention to grant a patent for the treatment of migraine by nasal administration of PH80 nasal spray, one of the Company's five rapid-onset investigational neuroactive pherine therapeutics. The patent claims also include treatment administered at the onset of migraine symptoms and treatment of migraines associated with traumatic brain injury.
Additionally, advancements in migraine nasal sprays mainly focus on minimizing side effects, such as dizziness, which are associated with some existing nasal spray formulations. Reducing these side effects can improve patient satisfaction. These advancements can enhance the efficiency of drug absorption through the nasal mucosa. Innovations that optimize drug delivery can make migraine nasal sprays more effective.
Further, the increasing prevalence of migraine, rising regulatory approvals such as FDA approvals, increasing clinical trials for the development of advanced nasal sprays, increasing awareness about the advantages of nasal sprays for migraine and advancements in the development of novel nasal sprays are the factors expected to drive the market over the forecast period.
Factors such as complications associated with the use of nasal sprays, adverse effects of using migraine nasal sprays such as bleeding from the nose and other long-term effects, and the high cost of the migraine nasal sprays are expected to hamper the market.
The global migraine nasal spray market is segmented based on chemical type, dosage, application, distribution channel and region.
The dihydroergotamine nasal spray segment is expected to hold the largest market share over the forecast period. Dihydroergotamine (DHE) nasal sprays are very well known for their effectiveness in providing relief from the various types of migraines. They especially work by constricting blood vessels in the brain, which can help alleviate the severe pain associated with migraines. The FDA approvals are increasing for approving the DHE-based nasal sprays for better patient outcomes. In addition, their wide adoption also increases the demand for the dihydroergotamine-based nasal spray.
For instance, in September 2021, Impel Pharmaceuticals received U.S. Food and Drug Administration (FDA) approval for Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults. The efficacy of currently approved DHE-based medications is well-established and they are widely used as part of the standard of care for the acute treatment of migraine. DHE, when reaching satisfactory systemic blood levels, is known to have fast onset and lasting effects for up to 48 hours.
Further, their wide availability, rapid effectiveness and acceptability help to hold the largest market share. DHE nasal sprays are favored for their relatively quick onset of action. They can provide faster relief than other migraine medications, making them a valuable option for individuals seeking rapid pain relief during a migraine attack. The nasal spray delivers the medication in a convenient way, especially for individuals who may experience nausea or difficulty swallowing during a migraine attack.
For instance, on May 21, 2020, Cipla Limited received final approval for its Abbreviated New Drug Application for Dihydroergotamine Mesylate Nasal Spray 4mg/mL from the United States Food and Drug Administration (FDA) with a Competitive Generic Therapy (CGT) designation.
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption of the migraine nasal sprays. North America especially the United States is known for its strong presence of major players such as medical device companies which are actively focusing on developing advanced nasal sprays that show better results in treating various types of migraines.
For instance, on November 16, 2021, Padagis launched its generic version of Zomig zolmitriptan nasal spray for the treatment of migraine headaches in patients aged 12 and older. In addition to the zolmitriptan nasal spray, Padagis markets azelastine, azelastine/fluticasone propionate, olopatadine, sumatriptan, and triamcinolone nasal sprays.
Furthermore, the increasing prevalence of migraine in the region is continuously increasing the adoption of migraine nasal sprays for treatment. For instance, according to the National Institute of Health (NIH), 2020, Migraine headache is a common, debilitating disease that causes significant disability. It affects nearly 1 in 7 Americans each year, with an estimated 40 million people suffering from migraine headaches. Its prevalence is as high as 19% for females and 9% for males. It is more commonly seen in females than males in the United States.
The major global players in the migraine nasal spray market include: Pfizer Inc., Impel Pharmaceuticals Inc., Upsher-Smith Laboratories, LLC., Lannett Company, GlaxoSmithKline plc, SteriMax Inc., Assertio Therapeutics, Inc., Cipla Inc., AstraZeneca Plc. And Dr. Reddy's Laboratories Ltd. Among others.
The COVID-19 pandemic significantly impacted the global migraine nasal spray market. During the pandemic, due to the tension and anxiety and the people staying at home increased the chances of migraines, which further increased the demand for nasal sprays for the treatment. For instance, according to the study conducted by the National Institute of Health (NIH) in 2023, the results show that 48.6% of migraine patients experienced worsened symptoms, 15.6% improved, and 35.8% remained unchanged. Worsening migraine symptoms were associated with staying at home during the lockdown. This increased number of migraine cases increased the demand for migraine nasal sprays.
The global migraine nasal spray market report would provide approximately 69 tables, 71 figures, and 187 Pages.
LIST NOT EXHAUSTIVE